Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.94
-8.3%
$24.97
$20.23
▼
$38.26
$2.49B2.231.90 million shs3.32 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.37
-4.4%
$51.78
$39.83
▼
$63.45
$4.13B1.921.60 million shs2.39 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.84
-0.2%
$28.81
$23.62
▼
$31.44
$164.33B0.3135.57 million shs30.83 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+101.82%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-8.41%-22.50%-10.78%-21.19%-3.59%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.90%+1.27%+13.76%+16.63%+39.67%
Pfizer Inc. stock logo
PFE
Pfizer
-0.17%-1.48%-2.49%+5.66%+15.01%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$41.03
$34.89
$16.10
▼
$41.14
$5.25B-0.247.54 million shs68.61 million shs
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$20.94
-8.3%
$24.97
$20.23
▼
$38.26
$2.49B2.231.90 million shs3.32 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$40.37
-4.4%
$51.78
$39.83
▼
$63.45
$4.13B1.921.60 million shs2.39 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,431.12
-0.9%
$1,247.93
$850.51
▼
$1,475.25
$1.34T0.43.00 million shs3.08 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$28.84
-0.2%
$28.81
$23.62
▼
$31.44
$164.33B0.3135.57 million shs30.83 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.00%0.00%0.00%0.00%+101.82%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-8.41%-22.50%-10.78%-21.19%-3.59%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-4.43%-19.32%-18.03%-23.79%-23.15%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
-0.90%+1.27%+13.76%+16.63%+39.67%
Pfizer Inc. stock logo
PFE
Pfizer
-0.17%-1.48%-2.49%+5.66%+15.01%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.11
Hold$38.00-7.38% Downside
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
2.75
Moderate Buy$47.64127.49% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.65
Moderate Buy$72.9380.65% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,422.00-0.64% Downside
Pfizer Inc. stock logo
PFE
Pfizer
2.18
Hold$30.325.12% Upside

Current Analyst Ratings Breakdown

Latest BEAM, LLY, CRSP, PFE, and APLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,400.00 ➝ $1,550.00
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Pfizer Inc. stock logo
PFE
Pfizer
Reiterated RatingMarket Perform$29.00
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/11/2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
Boost Price TargetOutperform$30.00 ➝ $33.00
11/10/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOverweight$110.00
11/9/2026
Pfizer Inc. stock logo
PFE
Pfizer
UpgradeHold (C) ➝ Hold (C+)
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
Set Price Target$34.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetBuy$33.00 ➝ $34.00
11/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
DowngradeBuy ➝ Hold
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$1.11B4.75$0.21 per share196.33$3.24 per share12.66
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
$139.74M15.51N/AN/A$9.20 per share2.28
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,115.64N/AN/A$16.99 per share2.38
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.66$25.20 per share56.78$42.81 per share33.43
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.63$4.40 per share6.56$15.67 per share1.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%N/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$79.99M-$1.04N/AN/AN/A-73.04%-32.76%-25.80%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.74N/AN/AN/A-1,812.07%-25.59%-17.89%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8146.4528.221.7131.90%86.76%22.03%2/3/2027 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.709.459.741.896.34%19.88%8.52%2/2/2027 (Estimated)

Latest BEAM, LLY, CRSP, PFE, and APLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
-$1.17-$1.28-$0.11-$1.28$8.75 million$0.31 million
11/3/2026Q3 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7350$0.87+$0.1350$0.56$15.85 billion$16.58 billion
11/2/2026Q3 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.06-$1.15-$0.09-$1.15$14.75 million$12.67 million
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.725.96%-13.20%245.71%16 Years

Latest BEAM, LLY, CRSP, PFE, and APLS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
10/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.435.85%11/6/202611/6/202612/7/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
0.87
3.63
3.16
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
0.11
13.01
13.00
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.36
16.21
16.21
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00
Pfizer Inc. stock logo
PFE
Pfizer
0.67
1.42
1.10

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
99.68%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770128.02 million119.70 millionOptionable
Beam Therapeutics Inc. stock logo
BEAM
Beam Therapeutics
540103.50 million99.56 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39397.00 million91.96 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Stock: What the Company Does and What Drives the Shares
Wall Street Zen Upgrades Pfizer (NYSE:PFE) to "Buy"
Wall Street Zen Upgrades Pfizer (NYSE:PFE) to Buy
Top Stock Reports for Visa, ExxonMobil & Pfizer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Beam Therapeutics stock logo

Beam Therapeutics NASDAQ:BEAM

$20.94 -1.89 (-8.28%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$20.94 0.00 (0.00%)
As of 05:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$40.37 -1.87 (-4.43%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$40.20 -0.17 (-0.43%)
As of 05:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,431.12 -12.38 (-0.86%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$1,430.03 -1.09 (-0.08%)
As of 05:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Pfizer stock logo

Pfizer NYSE:PFE

$28.84 -0.05 (-0.18%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$28.84 +0.01 (+0.02%)
As of 05:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.